Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vaxcyte, Inc. PCVX
$48.89
-$1.14 (-2.33%)
На 18:02, 12 мая 2023
+29.37%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
4913763149.00000000
-
week52high
54.84
-
week52low
17.44
-
Revenue
0
-
P/E TTM
-14
-
Beta
0.96176900
-
EPS
-3.83000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Buy | 07 июл 2020 г. | |
| Cantor Fitzgerald | Overweight | 07 июл 2020 г. | |
| BTIG | Buy | 17 ноя 2022 г. | |
| Needham | Buy | Buy | 03 янв 2023 г. |
| SVB Leerink | Outperform | 16 дек 2022 г. | |
| Guggenheim | Buy | 15 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lukatch Heath | D | 28000 | 315 | 10 янв 2023 г. |
| Lukatch Heath | D | 3125 | 82 | 10 янв 2023 г. |
| Lukatch Heath | D | 3207 | 233 | 10 янв 2023 г. |
| Lukatch Heath | A | 3440 | 315 | 10 янв 2023 г. |
| PICKERING GRANT | D | 302227 | 15158 | 30 дек 2022 г. |
| PICKERING GRANT | D | 108250 | 108250 | 30 дек 2022 г. |
| PICKERING GRANT | A | 374476 | 15158 | 30 дек 2022 г. |
| GUGGENHIME ANDREW | D | 430827 | 23691 | 30 дек 2022 г. |
| GUGGENHIME ANDREW | D | 42000 | 42000 | 30 дек 2022 г. |
| GUGGENHIME ANDREW | A | 61229 | 23691 | 30 дек 2022 г. |
Новостная лента
5 Best and Worst Performing Mid-Cap Stocks in Q4 2022
24/7 Wall Street
19 янв 2023 г. в 22:53
Mid-cap stocks are proving to be an attractive investment option over the past few years.
These Were The Five Best And Worst Performing Mid-Cap Stocks In October 2022
24/7 Wall Street
15 ноя 2022 г. в 20:22
Mid-cap companies lie in between the slower growth large-cap stocks and the faster-growth small-cap businesses.
Vaxcyte Has A Bright Future Ahead
Seeking Alpha
02 ноя 2022 г. в 15:01
Not everything is negative in this bearish market. The healthcare sector is home to stocks with rosy prospects.
Why Investors Are Suddenly Excited About Vaxcyte
MarketBeat
31 окт 2022 г. в 10:46
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.
Why Shares of Vaxcyte Rose 110.7% This Week
The Motley Fool
29 окт 2022 г. в 11:03
The company released early data for a promising pneumonia vaccine.